OMEICOS Therapeutics is dedicated to developing innovative therapies targeting inflammation and mitochondrial dysfunction, particularly for diseases with significant unmet medical needs. The company's lead compound, OMT-28, is a synthetic analog of the omega-3 fatty acid metabolite 17,18-EEQ, designed to enhance efficacy, safety, and oral bioavailability. OMT-28 has demonstrated a favorable safety profile in clinical trials, including a Phase 2 study for atrial fibrillation, where it positively impacted inflammatory biomarkers such as GDF-15 and IL-6. The company is also conducting a Phase II proof-of-concept study in patients with Primary Mitochondrial Disease (PMD) to further evaluate OMT-28's efficacy and safety.

OMEICOS leverages its extensive knowledge of omega-3 fatty acid metabolism to create a library of stable synthetic analogs that mimic the beneficial effects of natural epoxyeicosanoids. These compounds activate the AMPK/SIRT-1/PGC1-alpha pathway, promoting cell protection and reducing oxidative stress and inflammation. OMEICOS is exploring the potential of OMT-28 beyond cardiovascular applications, including severe eye disorders, where preclinical data suggest comparable efficacy to current treatments while offering the convenience of oral administration. The company's approach aims to unlock the therapeutic potential of omega-3 biology, addressing critical health challenges through innovative drug development.

Germany

OMEICOS Therapeutics has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat mitochondrial dysfunction, inflammatory, cardiovascular and other diseases. Epoxyeicosanoids activate cell type-specific endogenous pathways that promote organ and tissue protection.
OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. The currently active PMD-OPTION Phase 2a clinical study is evaluating OMEICOS’ lead development program OMT-28 in patients with Primary Mitochondrial Disease.

OMEICOS Therapeutics

Company Details